MANNKIND CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
MANNKIND CORP (MNKD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 0 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-08-05
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-03-31 was 0.00 shares.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 0.00 shares.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 0.00 shares.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 0.00 shares.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | 0.00 shares 10-K · filed 2026-02-26 | |||
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 0.00 shares 10-K · filed 2026-02-26 | |||
| 2023-12-31 | 0.00 shares 10-K · filed 2025-02-26 | |||
| 2022-12-31 | 0.00 shares 10-K · filed 2024-02-27 | |||
| 2021-12-31 | 0.00 shares 10-K · filed 2023-02-23 | |||
| 2011-03-03 | 1.47M shares 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |